Join our daily newsletter At The Bell to receive exclusive market insights
- OptiScan Imaging (OIL) has received a $350,000 order as part of its ongoing agreement with leading medical tech company Carl Zeiss Meditec (CZM)
- CZM is a long-time partner of OptiScan, with the two companies working together to create a pathology product called CONVIVO
- The recent orders from Carl Zeiss relate to the product, which gives real-time feedback on tissue microstructure through digital pathology consultation
- Along with the order’s announcement, OptiScan also revealed it netted $570,000 in receipts over the December quarter
- Shares in OIL are trading up 4.35 per cent at 12 cents each
OptiScan Imaging (OIL) has received a $350,000 order as part of its ongoing agreement with Carl Zeiss Meditec (CZM).
The ASX-listed healthcare stock and the global medical tech company are long-time partners, having created a pathology product together called CONVIVO.
This latest order from Carl Zeiss relates to CONVIVO, a product which gives real-time feedback on tissue microstructure through digital pathology consultation.
“The orders from CZM represent the continuation of CZM’s commercial rollout of the CONVIVO, developed as part of the co-operation agreement between CZM and OptiScan,” OIL CEO Darren Lurie explained.
Meanwhile, alongside the announcement on a new CZM order, OptiScan also used Wednesday’s market release to provide shareholders with a wider financial update.
The endomicroscopic imaging technologies business revealed it netted $570,000 in receipts over the December quarter.
The payments come from CZM, two sales of its FIVE2 (ViewnVivo) product to China-based customers and a grant from the BioMedTech Horizons Program.
“We are also very pleased that OptiScan continues to diversify its revenue streams and cash flows,” the OptiScan CEO said.
“Receipts in the December 2020 quarter included $570,000 from the final payments for the two FIVE2 (ViewnVivo) systems sold to China-based customers, the BioMedTech Horizons Program grant to support the University of Melbourne’s Melbourne Dental School trial and payments from CZM,” he added.
Shares in OptiScan Imaging are trading up 4.35 per cent at 12 cents each at 1:14 pm AEDT.
